Clinical Trial Update: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the P53MVA vaccine with pembrolizumab for recurrent platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• P53MVA (p53 MVA vaccine)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-08